Analysis of IFN-β and ISG15 transcript levels during infection in the presence and absence of ruxolitinib confirmed the ability of the drug to inhibit IFN signaling and ISG induction, but not the induction of IFN itself (Fig 8G and 8H). Here, IFNB1 is linked to infection.